[2-(4-chlorobenzylamino)ethyl]carbamic acid tert-butyl ester | 335059-94-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [2-(4-chlorobenzylamino)ethyl]carbamic acid tert-butyl ester
• 英文别名: tert-butyl 2-(4-chlorobenzylamino)ethylcarbamate；tert-Butyl (2-((4-chlorobenzyl)amino)ethyl)carbamate；tert-butyl N-[2-[(4-chlorophenyl)methylamino]ethyl]carbamate
• CAS: 335059-94-4
• 化学式: C₁₄H₂₁ClN₂O₂
• 分子量: 284.786
• InChiKey: LVNZSMOJVQTZDJ-UHFFFAOYSA-N

物化性质

• 沸点：
  402.8±30.0 °C(Predicted)
• 密度：
  1.119±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [2-(4-chlorobenzylamino)ethyl]carbamic acid tert-butyl ester 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以55%的产率得到1-(4-氯苄基)咪唑啉-2-酮
  参考文献：
  名称：

  Inhibitory effect of novel tetrahydropyrimidine-2(1H)-thiones on melanogenesis

  摘要：

  The series of imidazoldine-2-thiones 2 and tetrahydropyrimidine-2-thiones 3 were discovered as inhibitor of alpha-MSH-induced melanin production in melanoma B16 cells. The primary bioassay showed that 1-(4-ethylbenzyl)-tetrahydropyrimidine-2(1H)-thione 3e (> 100% inhibition at 10 mu M, IC50 = 1.2 mu M) and 1-(4-tert-butylbenzyl)-tetrahydropyrimidine-2(1H)-thione 3f (> 100% inhibition at 10 mu M, IC50 = 0.76 mu M) exhibited potent inhibitory effect against alpha-MSH-induced melanin production. Compounds 3 inhibit the biosynthesis of tyrosinase without affecting its catalytic activity in melanogenesis. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.12.044
• 作为产物：
  描述：

  tert-butyl N-[2-[(4-chlorophenyl)methylideneamino]ethyl]carbamate 在 sodium tetrahydroborate 、 三乙胺 作用下， 以 甲醇 为溶剂， 反应 0.5h， 生成 [2-(4-chlorobenzylamino)ethyl]carbamic acid tert-butyl ester
  参考文献：
  名称：

  Inhibitory effect of novel tetrahydropyrimidine-2(1H)-thiones on melanogenesis

  摘要：

  The series of imidazoldine-2-thiones 2 and tetrahydropyrimidine-2-thiones 3 were discovered as inhibitor of alpha-MSH-induced melanin production in melanoma B16 cells. The primary bioassay showed that 1-(4-ethylbenzyl)-tetrahydropyrimidine-2(1H)-thione 3e (> 100% inhibition at 10 mu M, IC50 = 1.2 mu M) and 1-(4-tert-butylbenzyl)-tetrahydropyrimidine-2(1H)-thione 3f (> 100% inhibition at 10 mu M, IC50 = 0.76 mu M) exhibited potent inhibitory effect against alpha-MSH-induced melanin production. Compounds 3 inhibit the biosynthesis of tyrosinase without affecting its catalytic activity in melanogenesis. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.12.044

文献信息

• [EN] PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS<br/>[FR] PYRIMIDYL CYCLOPENTANES UTILSÉS COMME INHIBITEURS DE LA PROTÉINE KINASE AKT
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2009006569A1

  公开（公告）日：2009-01-08

  The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供了一种I式化合物，包括互变异构体、已分离的对映体、非对映异构体、溶剂合物、代谢物、盐和其药学上可接受的前药。还提供了使用该发明的化合物作为AKT蛋白激酶抑制剂和用于治疗癌症等高增殖性疾病的方法。
• AKT protein kinase inhibitors
  申请人：Mitchell S. Ian

  公开号：US20050130954A1

  公开（公告）日：2005-06-16

  The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供化合物，包括已解决的对映体、二对映异构体、溶剂化物和药学上可接受的盐，其包括公式：A-L-CR，其中CR是一个环核心基团，L是一个连接基团，A如此处所定义。同时提供了使用本发明化合物作为AKT蛋白激酶抑制剂和用于治疗增殖性疾病如癌症的方法。
• PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
  申请人：Bencsik Josef R.

  公开号：US20110160221A1

  公开（公告）日：2011-06-30

  The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供了式I的化合物，包括互变异构体、已分离的对映异构体、二对映异构体、溶剂化物、代谢物、盐和其药学上可接受的前药。本发明还提供了使用这些化合物作为AKT蛋白激酶抑制剂和治疗癌症等增生性疾病的方法。
• AKT PROTEIN KINASE INHIBITORS
  申请人：Mitchell Ian S.

  公开号：US20100168123A1

  公开（公告）日：2010-07-01

  The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供了化合物，包括已分离的对映体、非对映异构体、溶剂化物和药学上可接受的盐，其包括式子：A-L-CR，其中CR是一个环状核心基团，L是一个连接基团，A如上所定义。本发明还提供了使用这些化合物作为AKT蛋白激酶抑制剂和治疗增殖性疾病，如癌症的方法。
• Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
  申请人：Bencsik Josef R.

  公开号：US08377937B2

  公开（公告）日：2013-02-19

  The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供了I式化合物，包括互变异构体、已分离的对映体、非对映异构体、溶剂化物、代谢产物、盐以及其药学上可接受的前药。同时，还提供了使用本发明的化合物作为AKT蛋白激酶抑制剂以及用于治疗高增殖性疾病，如癌症的方法。